Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PMGC Holdings Inc. (ELAB)
USD1.08
-0.04 (-3.57%)
US NASDAQ Healthcare Biotechnology
Address
120 Newport Center Drive 92660
Newport Beach, CA, US
Newport Beach, CA, US
CEO
Graydon Bensler
Website
pmgcholdings.com
IPO
2023-11-21
CIK 1840563 ISIN US73017P5089
Description
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.08
-0.04 (-3.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
-0.24
Float Shares
1.93M
Free Float %
99.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.69% | +0.57% | -29.72% | -76.85% | -99.65% | -98.77% | -99.78% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.08
Quality scores
Altman Z-Score
-2.14
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-76.1%
-
EPS growth Biotechnology: +29.7%+94.3% ★ Q1'26: +95.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,248.4% Q1'26: -490.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,250.1% Q1'26: -487.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-145.2% Q1'26: -242.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2,049.1% Q1'26: +6,754.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.36× Q1'26: -0.63× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
91.3K
OE per share TTM
188.06
Owner's Yield
11.74%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
49.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
6
Total invested
388.3K
Insider transactions (90d)
0
Beneficial owners (>5%)
17
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Altium Capital Management, LP | 5.71M | 9.99% | — | 5.71M | — | — | IA, PN | Delaware, United States of America | 2024-09-26 | ↗ |
| 2 | Altium Growth Fund, LP | 5.71M | 9.99% | — | 5.71M | — | — | PN | Delaware, United States of America | 2024-09-26 | ↗ |
| 3 | Altium Growth GP, LLC | 5.71M | 9.99% | — | 5.71M | — | — | OO | Delaware, United States of America | 2024-09-26 | ↗ |
| 4 | Braeden Lichti | 3.82M | 22.07% | 3.82M | — | 3.82M | — | IN | Canada | 2024-02-21 | ↗ |
| 5 | L1 Capital Global Opportunities Master Fund, Ltd. | 3.17M | 9.99% | 3.17M | — | — | — | FI | Cayman Islands | 2024-10-01 | ↗ |
| 6 | S.H.N. Financial Investments Ltd. | 3.04M | 9.99% | 3.04M | — | — | — | OO | Israel | 2024-10-02 | ↗ |
| 7 | Jordan R. Plews | 3.00M | 17.00% | 3.00M | — | 3.00M | — | IN | United States | 2024-02-14 | ↗ |
| 8 | JP Bio Consulting LLC, 85-1618883 | 2.85M | 16.50% | 2.85M | — | 2.85M | — | IN | United States | 2024-02-14 | ↗ |
| 9 | Amin Nathoo | 2.24M | 9.90% | — | 2.24M | — | 2.24M | HC, IN | Texas | 2024-11-14 | ↗ |
| 10 | Anson Advisors Inc. | 2.24M | 9.90% | — | 2.24M | — | 2.24M | FI, CO | Texas | 2024-11-14 | ↗ |
| 11 | Anson Funds Management LP | 2.24M | 9.90% | — | 2.24M | — | 2.24M | IA, PN | Texas | 2024-11-14 | ↗ |
| 12 | Anson Management GP LLC | 2.24M | 9.90% | — | 2.24M | — | 2.24M | HC, OO | Texas | 2024-11-14 | ↗ |
| 13 | Moez Kassam | 2.24M | 9.90% | — | 2.24M | — | 2.24M | HC, IN | Texas | 2024-11-14 | ↗ |
| 14 | Tony Moore | 2.24M | 9.90% | — | 2.24M | — | 2.24M | HC, IN | Texas | 2024-11-14 | ↗ |
| 15 | Hatem Abou-Sayed | 1.52M | 8.70% | 1.52M | — | 1.52M | — | IN | United States | 2024-02-14 | ↗ |
| 16 | Hatem Abou-Sayed MD MBA FACS, a Professional Medical Corporation, 81-4061571 | 1.37M | 7.90% | 1.37M | — | 1.37M | — | IN | United States | 2024-02-14 | ↗ |
| 17 | MOA Life Plus Co., Ltd. | 950.0K | 5.03% | 950.0K | — | 950.0K | — | CO | Korea | 2024-05-31 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
6
+6 vs prev Q
New positions
6
Closed positions
0
Increased
6
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | 31.6K +31.6K (+100.0%) | 189.2K +189.2K (+100.0%) | 315.94% +315.940 pp | 0.00% +0.000 pp | USD5.99 +0.0% | 1 qtrs NEW |
| 2 | MORGAN STANLEY | 15.0K +15.0K (+100.0%) | 89.9K +89.9K (+100.0%) | 150.00% +150.000 pp | 0.00% +0.000 pp | USD5.99 +0.0% | 1 qtrs NEW |
| 3 | SCHONFELD STRATEGIC ADVISORS LLC | 14.8K +14.8K (+100.0%) | 88.7K +88.7K (+100.0%) | 148.00% +148.000 pp | 0.00% +0.001 pp | USD5.99 +0.0% | 1 qtrs NEW |
| 4 | IFP ADVISORS, INC | 2.0K +2.0K (+100.0%) | 12.0K +12.0K (+100.0%) | 20.00% +20.000 pp | 0.00% +0.000 pp | USD5.99 +0.0% | 1 qtrs NEW |
| 5 | UBS GROUP AG | 1.3K +1.3K (+100.0%) | 7.8K +7.8K (+100.0%) | 13.02% +13.020 pp | 0.00% +0.000 pp | USD5.99 +0.0% | 1 qtrs NEW |
| 6 | TOWER RESEARCH CAPITAL LLC (TRC) | 129.00 +129.0 (+100.0%) | 773.00 +773.0 (+100.0%) | 1.29% +1.290 pp | 0.00% +0.000 pp | USD5.98 +0.2% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-26 | Braeden Lichti | Director / 10% Owner | A-Award | A | Series B Preferred Stock | 3,336,437 | 0.00 | — | 3,336,437 | I | ↗ |
| 2025-03-26 | Bensler Graydon | Director / Officer / 10% Owner | A-Award | A | Series B Preferred Stock | 3,036,437 | 0.00 | — | 3,036,437 | I | ↗ |
| 2025-03-06 | Kovalyov George | Director | — | — | Options to Purchase Common Stock | 5 | 19,600.00 | 98.0K | 0 | D | ↗ |
| 2024-03-06 | Kovalyov George | Director | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2023-11-13 | Parry Jeffrey | Director | — | — | Common Stock | 0 | 0.00 | — | 3 | D | ↗ |
| 2023-11-13 | Daley Juliana | Director | — | — | Common Stock | 0 | 0.00 | — | 1 | D | ↗ |
| 2023-11-13 | Bensler Graydon | Director / Officer | — | — | Common Stock | 0 | 0.00 | — | 983,120 | D | ↗ |
| 2023-06-01 | Daley Juliana | Director | — | — | Options to Purchase Common Stock | 4 | 98,000.00 | 392.0K | 0 | D | ↗ |
| 2022-09-30 | Parry Jeffrey | Director | — | — | Options to Purchase Common Stock | 4 | 98,000.00 | 392.0K | 0 | D | ↗ |
| 2021-01-15 | Bensler Graydon | Director / Officer | — | — | Stock Option | 200,000 | 0.60 | 120.0K | 0 | D | ↗ |
| 2005-07-26 | PATTERSON MARK R | Director | M-Exempt | D | Stock Option (right to buy) | 20,000 | 10.34 | 206.7K | 0 | — | ↗ |
| 2005-07-26 | KARP DOUGLAS M | Director | M-Exempt | A | Common Stock | 20,000 | 10.34 | 206.7K | 0 | — | ↗ |
| 2005-07-26 | GRANSEE DAVID H | Officer | M-Exempt | A | Common Stock | 4,800 | 1.05 | 5.0K | 0 | — | ↗ |
| 2005-07-20 | PATTERSON MARK R | Director | U-Tender | D | Common Stock | 23,000 | 31.00 | 713.0K | 0 | — | ↗ |
| 2005-02-16 | PATTERSON MARK R | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 28.75 | 575.0K | 20,000 | — | ↗ |
| 2005-02-16 | KARP DOUGLAS M | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 28.75 | 575.0K | 20,000 | — | ↗ |
| 2005-02-16 | GRANSEE DAVID H | Officer | A-Award | A | Stock Options (right to buy) | 6,000 | 28.75 | 172.5K | 6,000 | — | ↗ |
| 2004-08-12 | GRANSEE DAVID H | Officer | M-Exempt | A | Common Stock | 6,400 | 9.13 | 58.4K | 0 | — | ↗ |
| 2004-03-04 | PATTERSON MARK R | Director | A-Award | A | Stock Options (right to buy) | 10,000 | 58.71 | 587.1K | 10,000 | — | ↗ |
| 2004-03-04 | KARP DOUGLAS M | Director | A-Award | A | Stock Options (right to buy) | 10,000 | 58.71 | 587.1K | 10,000 | — | ↗ |
| 2004-02-24 | GRANSEE DAVID H | Officer | A-Award | A | Stock Options (right to buy) | 3,000 | 58.64 | 175.9K | 3,000 | — | ↗ |
| 2004-02-23 | GRANSEE DAVID H | Officer | M-Exempt | D | Stock Options (right to buy) | 6,600 | 2.10 | 13.9K | 0 | — | ↗ |
| 2003-09-08 | GRANSEE DAVID H | Officer | A-Award | A | Stock Options (right to buy) | 10,000 | 35.01 | 350.1K | 10,000 | — | ↗ |
| 2003-03-04 | PATTERSON MARK R | Director | A-Award | A | Stock Options (right to buy) | 10,000 | 58.71 | 587.1K | 10,000 | — | ↗ |
| 2003-03-04 | KARP DOUGLAS M | Director | A-Award | A | Stock Options (right to buy) | 10,000 | 58.71 | 587.1K | 10,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-36.9K
Shares Outstanding
1.94M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Graydon Bensler Non-Employee, Non-Executive Chief Executive Officer, Chief Financial Officer and Director | 196.3K | 195.0K | — | — | — | — | 391.3K | 0.00% | ↗ |
| 2 | 2024 | Jordan R. Plews Former Director, Chief Executive Officer, and President | 228.3K | 25.0K | — | — | — | — | 253.3K | 0.00% | ↗ |
| 3 | 2024 | Brenda Buechler Former Chief Marketing Officer | 98.5K | 20.0K | — | — | — | — | 118.5K | 0.00% | ↗ |
| 4 | 2024 | Christoph Kraneiss Former Commercial Officer | 92.2K | 20.0K | — | — | — | — | 112.2K | 0.00% | ↗ |
| 5 | 2023 | Jordan R. Plews Former Director, Chief Executive Officer, and President | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
| 6 | 2023 | Brenda Buechler Former Chief Marketing Officer | 190.0K | — | — | — | — | — | 190.0K | 0.00% | ↗ |
| 7 | 2023 | Christoph Kraneiss Former Commercial Officer | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 8 | 2023 | Graydon Bensler Non-Employee, Non-Executive Chief Executive Officer, Chief Financial Officer and Director | 85.0K | 25.0K | — | — | — | — | 110.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Graydon Bensler | Chief Executive Officer, Chief Financial Officer, Secretary & Director | 697.8K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ELAB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
